How to best manage interstitial lung disease (ILD) is a contentious issue, one involving multidisciplinary, and of en divisive, discussion between pulmonologists, rheumatologists, and radiologists. T is is because the cause of ILD-a diverse group of disorders in which the connective tissue of the lungs becomes inf amed and f brotic-is of en unclear and its dif erent forms ill-def ned (1) . Some forms of ILD are relatively straightforward, arising from an infection or from exposure to certain drugs or hazardous materials. Other forms are known to develop in association with autoimmune diseases called connective tissue disorders (CTDs), yet their precise etiology remains elusive. Even more perplexing are the ILD forms deemed idiopathic, although these cases sometimes turn out to be an early manifestation of CTD-associated ILD (CTD-ILD). Because CTD-ILD occurs in the setting of systemic autoimmunity, and even idiopathic ILD may be associated with signs of autoimmunity, there has been much debate about a possible role for autoimmunity in the pathogenesis of ILD (1-7). But no autoimmune mechanism has been evinced-until now. In this issue of Science Translational Medicine, Shum and colleagues (8) show that in a subset of CTD-ILD and idiopathic-ILD cases, autoimmune targeting of a lung-specif c protein may be at the root of the disease.
A LUNG-SPECIFIC AUTOANTIGEN
Indirect evidence for an autoimmune etiology of ILD has come from the detection of immune-cell inf ltrates in the lungs and autoantibodies in the blood and bronchoalveolar lavage f uid, not only in CTD-ILD but surprisingly also in idiopathic ILD (1) (2) (3) (4) (5) (6) . Moreover, in idiopathic ILD certain autoantibodies appear to be associated with more severe disease (6) or with acute exacerbation of disease (4) . However, none of these autoantibodies targets lung-specif c proteins, so it is unclear (i) whether their presence simply ref ects the systemic autoimmunity underlying the associated CTD in CTD-ILD and (ii) how they could cause disease that is limited to the lungs in idiopathic ILD. Some insight into this conundrum might be gleaned from studies on lung disease that develops in patients with autoimmune polyendocrine syndrome type 1 (APS1), a rare autoimmune disorder. Alimohammadi et al. (9) showed that APS1 patients with respiratory symptoms have autoantibodies to KCNRG, a potassium channel-regulating protein preferentially expressed in the bronchiolar epithelium. Finding that loss of immune tolerance to BPIFB9 (also known as vomeromodulin) can cause ILD-like lung pathology in mice, Shum et al. (7) used this information to identify autoantibodies to the related lung-specif c protein BPIFB1 (BPIFB9 is a pseudogene in humans) in a patient with APS1-ILD.
In this issue of Science Translational Medicine, Shum et al. (8) broaden their scope, shedding light on the relevance of autoimmunity to the pathogenesis of the more common and inscrutable forms of ILD. T ey started once more by studying APS1-ILD but then extended their f ndings to CTD-ILD and idiopathic ILD. Because APS1 involves production of autoantibodies to organspecif c antigens and is a well-characterized monogenic disorder caused by defects in the autoimmune regulator (AIRE) gene, the authors reasoned that studying autoimmune responses in patients with APS1, as well as in mice with an equivalent defect in Aire, would yield mechanistic insights into the pathogenesis of ILD that have so far been lackingand, importantly, answer the question of whether autoimmunity can cause ILD.
T e authors previously detected autoantibodies to BPIFB1 in the blood of a single APS1 patient (7) . In the new study (8) , they screened a large cohort (n = 104) of APS1 patients with and without ILD and found that BPIFB1 autoantibodies were present in the blood of only a small proportion of the total cohort of APS1 patients but were present in all six of the APS1 patients with ILD. Shum and colleagues then showed that expression of human BPIFB1 is restricted to the lungs and thymus. T is expression pattern is telling because the way in which AIRE promotes immune tolerance is by orchestrating the ectopic expression of tissue-specif c antigens in the thymus, brokering an encounter between them and maturing T cells; this process-called central tolerance-results in the purging of potentially dangerous T cells that react too strongly with these antigens (10) . T ese new f ndings (8) suggest that BPIFB1 is a lung-specif c protein that normally enjoys AIRE-mediated protection from autoimmune attack, protection that is compromised in APS1. Indeed, in immunof uorescence experiments, antibodies in APS1-ILD serum bound to BPIFB1 present in human bronchiolar epithelium (Fig. 1) . Together, these f ndings identify BPIFB1 as a lung-specif c autoantigen in APS1-ILD.
T e authors next showed that BPIFB1 autoantibodies were also present in a subset of patients with CTD-associated ILD-and even in a subset of patients with idiopathic ILD (Fig. 1) (8) . T ese autoantibodies were not present in healthy individuals, nor in patients with type I diabetes, an autoimmune disorder that does not feature lung pathology-indicating that the autoantibodies are not simply a general biomarker of systemic autoimmunity but rather an indicator of lung-specif c autoimmunity in diverse types of ILD. 
PROVING CAUSATION

FOCUS
showed that BPIFB9-specif c autoimmunity and lung disease developed in mice with Aire −/− thymi but not in those with Aire +/− thymi, conf rming that defects in central tolerance to a lung antigen can cause ILD. However, it is BPIFB1, not BPIFB9, that is targeted in human ILD, and most cases of ILD-those not linked to APS1-are not associated with a known defect in AIRE. Shum et al. (8) therefore used a dif erent mouse model to determine whether a break in tolerance could result in BPIFB1 targeting and, hence, ILD. Because B p i f 1 −/− mice have not previously encountered BPIFB1, they have not developed immune tolerance to this protein, so that immunization of these mice with BPIFB1 induces anti-BPIFB1 immune responses. Transfer of BPIFB1-specif c lymphocytes from BPIFB1-immunized B p i f 1 −/− mice to lymphocyted e f c i e n t B p i f 1 +/+ mice induced ILD in the recipient mice, indicating that autoimmune targeting of BPIFB1-independent of a defect in Aire-can also cause ILD.
QUESTIONS AND CLINICAL IMPLICATIONS
T us, by using a well-characterized but rare disorder as a starting point, Shum et al. (8) demonstrated that lung-specif c autoimmunity may cause ILD associated with more common diseases, as well as ILD so far deemed idiopathic. T is exciting f nding increases our understanding of ILD and raises a slew of questions:
How do the autoantibodies to BPIFB1 arise in CTD-ILD and idiopathic ILD? Do they arise as a result of unknown AIRE defects that are subtler than those in APS1, or as a result of AIRE-independent defects in peripheral tolerance (which complements central tolerance), or both? With this in mind, do Aire −/− mice with ILD develop autoantibodies to BPIFB1, in addition to autoantibodies to BPIFB9? Do ILD patients with autoantibodies to BPIFB1 have BPIFB1-specif c T cells in their lungs? What is the relationship between autoantibodies to BPIFB1 and the other ILD-associated autoantibodies identif ed, especially the lungspecif c autoantigen KCNRG (9)? Are they present in the same or in distinct patient subsets? What causes CTD-ILD and idiopathic ILD in patients who do not have autoantibodies to BPIFB1? Is the ILD of autoimmune origin in these patients as well, involving targeting of a dif erent lung autoantigen, or is it not autoimmune but rather the result of unrecognized exposures or other factors? Might autoimmunity even contribute to yet other forms of ILD? For example, in infection-triggered ILD, protective immune responses could conceivably segue to pathogenic autoimmune responses through cross-reactivity. What other socalled idiopathic diseases might in fact be autoimmune in origin?
T e f ndings also have important implications for disease management. Although it remains to be tested in an independent patient cohort, the ability of autoantibodies to BPIFB1 to identify autoimmune-driven ILD could prove transformative. A biomarker enabling identif cation of individuals whose ILD is of autoimmune origin would allow more ef ective management of their pulmonary disease, by indicating the need for immunomodulatory treatment. Indeed, idiopathic ILD has, in general, a worse prognosis than CTD-ILD, possibly because individuals with CTD-ILD are more likely to be treated with immunosuppressive drugs (aimed at tackling the autoimmunity underlying CTDs) (1) . Perhaps autoantibodies to BPIFB1 will also prove useful as biomarkers that predict the onset or progression of ILD, which would allow for preventive interventions. Moreover, if BPIFB1 is indeed a critical lung autoantigen, development of antigenspecif c tolerizing therapies for autoimmune ILD becomes a possibility. Even if the promise of biomarker tests and tolerizing therapies based on BPIFB1 is not borne out, the f nd- ings by Shum et al. substantiate the idea that lung-directed autoimmunity can cause ILD. T us, the stage is set for further dissection of the role of autoimmunity and the benef t of immunomodulatory treatment in ILD, as well as the classif cation of ILD on the basis of mechanism rather than association.
